News & Updates

SGLT2 inhibitors beneficial in Chinese patients with type 2 diabetes

15 Jun 2022 by

A Singapore study has reported good real-world experience with sodium-glucose co-transporter-2 (SGLT2) inhibitors, which are well tolerated and effective at improving blood sugar and lowering complications risk.

SGLT2 inhibitors beneficial in Chinese patients with type 2 diabetes

15 Jun 2022

Is SGLT-2 inhibitor better than metformin as first-line T2D treatment?

15 Jun 2022

Use of sodium–glucose cotransporter-2 inhibitors (SGLT-2i) as first-line treatment for type 2 diabetes (T2D) delivers a comparable risk for myocardial infarction (MI), stroke, and mortality; a lower risk for hospitalization for heart failure (HHF)/mortality and HHF; and a similar safety profile, except for a higher risk for genital infections, when compared to treatment with metformin, a study has found.

Is SGLT-2 inhibitor better than metformin as first-line T2D treatment?

15 Jun 2022

How effective is adjunctive dexmedetomidine for alcohol withdrawal in ICU patients?

15 Jun 2022

In critically ill patients with alcohol withdrawal syndrome (AWS), adding dexmedetomidine to symptom-triggered benzodiazepines appears to cause no significant change in Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scores from baseline compared to symptom-triggered therapy alone, a recent study has found.

How effective is adjunctive dexmedetomidine for alcohol withdrawal in ICU patients?

15 Jun 2022

Sarilumab shows potential for relapsing polymyalgia rheumatica

15 Jun 2022 by

The monoclonal antibody sarilumab demonstrated significant efficacy in individuals with relapsing polymyalgia rheumatica (PMR), findings from the phase III SAPHYR trial have shown.

Sarilumab shows potential for relapsing polymyalgia rheumatica

15 Jun 2022

$Trifluridine/tipiracil polypill shows modest clinical activity against refractory ESCC$

Trifluridine/tipiracil polypill shows modest clinical activity against refractory ESCC

15 Jun 2022

The fixed-dose combination of trifluridine/tipiracil may be feasible for use in the treatment of patients with refractory esophageal squamous cell carcinoma (ESCC), with the drug showing modest clinical activity in the phase II ECTAS study.

Trifluridine/tipiracil polypill shows modest clinical activity against refractory ESCC

15 Jun 2022

Original New Drug Application Approvals by US FDA (01 - 15 June 2022)

15 Jun 2022

New drug applications approved by US FDA as of 01 - 15 June 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01 - 15 June 2022)

15 Jun 2022

Venetoclax boosts HRQoL in AML patients unfit for intensive chemotherapy

14 Jun 2022

Drug combinations including venetoclax seem to have a positive impact on health-related quality of life (HRQoL), or at least does not worsen it, in patients with acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy, a recent study has found.

Venetoclax boosts HRQoL in AML patients unfit for intensive chemotherapy

14 Jun 2022

Beta-blocker use reduces daily physical activity

14 Jun 2022

Treatment with beta-blockers in hypertension may decrease daily physical activity but not maximal exercise performance, a study has found.

Beta-blocker use reduces daily physical activity

14 Jun 2022

Amiodarone use may reduce survival in continuous‐flow left ventricular assist device recipients

14 Jun 2022

For patients who have undergone continuous‐flow left ventricular assist device (CF‐LVAD) implantation, treatment with amiodarone may do more harm than good, with a recent study showing that it contributes to increased risk of mortality.

Amiodarone use may reduce survival in continuous‐flow left ventricular assist device recipients

14 Jun 2022

Prophylactic 5-FU plus heparin not effective against proliferative vitreoretinopathy in RRD

14 Jun 2022

Adjuvant therapy with 5-fluorouracil (5-FU) and low molecular weight heparin in high-risk patients with rhegmatogenous retinal detachment (RRD) does not help prevent the development of proliferative vitreoretinopathy, as shown in a study.

Prophylactic 5-FU plus heparin not effective against proliferative vitreoretinopathy in RRD

14 Jun 2022

News & Updates

Filter by Specialty:

Specialty:

SGLT2 inhibitors beneficial in Chinese patients with type 2 diabetes

SGLT2 inhibitors beneficial in Chinese patients with type 2 diabetes

Is SGLT-2 inhibitor better than metformin as first-line T2D treatment?

Is SGLT-2 inhibitor better than metformin as first-line T2D treatment?

How effective is adjunctive dexmedetomidine for alcohol withdrawal in ICU patients?

How effective is adjunctive dexmedetomidine for alcohol withdrawal in ICU patients?

Sarilumab shows potential for relapsing polymyalgia rheumatica

Sarilumab shows potential for relapsing polymyalgia rheumatica

Trifluridine/tipiracil polypill shows modest clinical activity against refractory ESCC

Trifluridine/tipiracil polypill shows modest clinical activity against refractory ESCC

Original New Drug Application Approvals by US FDA (01 - 15 June 2022)

Original New Drug Application Approvals by US FDA (01 - 15 June 2022)

Venetoclax boosts HRQoL in AML patients unfit for intensive chemotherapy

Venetoclax boosts HRQoL in AML patients unfit for intensive chemotherapy

Beta-blocker use reduces daily physical activity

Beta-blocker use reduces daily physical activity

Amiodarone use may reduce survival in continuous‐flow left ventricular assist device recipients

Amiodarone use may reduce survival in continuous‐flow left ventricular assist device recipients

Prophylactic 5-FU plus heparin not effective against proliferative vitreoretinopathy in RRD

Prophylactic 5-FU plus heparin not effective against proliferative vitreoretinopathy in RRD